Research Focus

Medicine; Assistant Attending

Recent additions – View all

1. SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)

   Meeting Abstract

   Rathkopf, D.; Dallos, M.; Stein, M.; Spina, C. S.; Deutsch, I.; Nguyen, C.; Okada, A.; Lloyd, M.; Manarite, J.; McBride, S.
   Annals of Oncology (2024)

   Fulltext@MSK | Save
2. Androgen deprivation therapy drives a distinct immune phenotype in localized prostate cancer

   Journal Article

   Dallos, M. C.; Obradovic, A. Z.; McCann, P.; Chowdhury, N.; Pratapa, A.; Aggen, D. H.; Gaffney, C.; Autio, K. A.; Virk, R. K.; De Marzo, A. M.; more...
   Clinical Cancer Research (2024)

   Fulltext@MSK | Save
3. Chemotactic signaling pathways in prostate cancer: Implications in the tumor microenvironment and as potential therapeutic targets

   Journal Article

   Lopez-Bujanda, Z. A.; Hadavi, S. H.; Ruiz De Porras, V.; Martínez-Balibrea; Dallos, M. C.
   International Review of Cell and Molecular Biology (2024)

   Fulltext@MSK | Save